Visits analyzed (12,094 visits; 1776 patients)* | ||||
---|---|---|---|---|
Visits with MTC, % ACR20 response (95% CI) | Visits without MTC, % ACR20 response (95% CI) | RD (95% CI) | RR (95% CI) | |
DAS28 category | ||||
Overall effect | 12.7 (11.2–14.1) | 7.3 (6.8–7.0) | 5.4 (4.0–6.0) | 1.7 (1.5–2.0) |
Remission and low (< 3.20) | 2.0 (0.9–3.4) | 1.2 (0.8–1.7) | 0.9 (− 0.4–2.3) | 1.7 (0.7–3.4) |
Low moderate (3.20–4.02) | 10.8 (7.8–14.2) | 5.1 (4.0–6.7) | 5.7 (2.4–9.3) | 2.1 (1.4–3.1) |
High moderate (4.03–5.10) | 19.7 (16.7–23.2) | 12.2 (10.2–14.4) | 7.4 (3.8–11.4) | 1.6 (1.3–2.0) |
High (> 5.10) | 34.7 (31.1–38.5) | 20.2 (16.9–23.5) | 14.5 (10.6–18.7) | 1.7 (1.5–2.1) |
CDAI category | ||||
Overall effect | 12.4 (11.0–13.8) | 7.4 (6.9–7.2) | 4.9 (3.4–5.5) | 1.7 (1.5–1.9) |
Remission and low (< 10.0) | 1.3 (0.5–2.5) | 1.1 (0.7–1.6) | 0.2 (− 0.8–1.3) | 1.2 (0.4–2.6) |
Low moderate (10.0–12.9) | 8.2 (4.5–13.0) | 5.4 (3.9–7.3) | 2.9 (− 1.2–7.7) | 1.5 (0.8–2.7) |
High moderate (13.0–22.0) | 20.3 (17.3–23.8) | 10.3 (8.2–12.2) | 10.0 (6.3–14.0) | 2.0 (1.5–2.5) |
High (> 22.0) | 31.2 (27.6–34.6) | 19.8 (16.9–23.2) | 11.4 (7.6–14.9) | 1.6 (1.4–1.8) |
RAPID3 category | ||||
Overall effect | 16.3 (14.5–17.2) | 7.0 (6.1–7.6) | 9.3 (7.4–10.7) | 2.3 (2.0–2.7) |
Remission and low (< 2.00) | 5.9 (3.5–8.8) | 2.9 (2.0–3.9) | 3.1 (0.6–5.9) | 2.1 (1.2–3.4) |
Low moderate (2.00–3.81) | 15.2 (12.2–18.4) | 5.9 (4.8–7.3) | 9.3 (6.1–12.7) | 2.6 (1.9–3.4) |
High moderate (3.82–4.00) | 11.8 (5.2–19.4) | 6.5 (3.2–10.1) | 5.3 (− 2.7–14.0) | 1.8 (0.7–4.3) |
High (> 4.00) | 22.3 (19.7–24.3) | 9.7 (8.4–11.1) | 12.5 (9.7–14.9) | 2.3 (1.9–2.7) |